Sophie PIPERNO-NEUMANN
Institut Curie · Institut Curie Paris
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sophie PIPERNO-NEUMANN as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:55 UTC. Open this list on ClinicalTrials.gov
- N/ANCT04424719 · Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)Institut Curie · recruiting · Uveal Melanoma · principal investigator
- N/ANCT04055220 · Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone SarcomasCentre Leon Berard · recruiting · Bone Sarcoma, Osteosarcoma, Ewing Sarcoma · principal investigator
- Ph3NCT02843386 · Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal MelanomaInstitut Curie · completed · Uveal Melanoma · principal investigator
- N/ANCT01334008 · Study of Circulating Tumoral DNA in Metastatic Choroidal MelanomaInstitut Curie · completed · Choroidal Melanoma, Diffuse · principal investigator
- Ph2NCT01217398 · Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the EyeInstitut Curie · unknown · Intraocular Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:55 UTC. The ranking covers the 200 most relevant of 54 PubMed records, and a shared surname and initials can bring in a namesake. All 54 on PubMed
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.N Engl J Med · 2021769 citationsRCR 39.3
- Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.J Clin Oncol · 2008504 citationsRCR 12.9
- Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.JAMA Oncol · 2018365 citationsRCR 12.0
- Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.Lancet Oncol · 2020276 citationsRCR 13.1
- Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.Lancet Oncol · 2019273 citationsRCR 10.7
- Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.N Engl J Med · 2023264 citationsRCR 22.2
- Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort.Nat Med · 2022261 citationsRCR 15.7
- Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet Oncol · 2016242 citationsRCR 8.3
- Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).J Clin Oncol · 2018218 citationsRCR 7.5
- 176 citationsRCR 5.3